Abbott Laboratories (NYSE:ABT) has been given an average recommendation of “Buy” by the twenty-three research firms that are presently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $66.12.

Several brokerages have recently weighed in on ABT. Barclays upped their price objective on Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Abbott Laboratories in a report on Thursday, January 25th. Royal Bank of Canada restated a “buy” rating and issued a $67.00 price objective on shares of Abbott Laboratories in a report on Thursday, January 25th. Leerink Swann restated a “market perform” rating and issued a $68.00 price objective (up previously from $60.00) on shares of Abbott Laboratories in a report on Thursday, January 25th. Finally, Citigroup upped their price objective on Abbott Laboratories from $59.00 to $64.00 and gave the company a “neutral” rating in a report on Tuesday, January 30th.

Shares of Abbott Laboratories (ABT) opened at $57.64 on Wednesday. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $99,927.90, a price-to-earnings ratio of 221.70, a PEG ratio of 1.72 and a beta of 1.55. Abbott Laboratories has a twelve month low of $42.31 and a twelve month high of $64.60.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $7.59 billion during the quarter, compared to analyst estimates of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The company’s revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.65 earnings per share. analysts forecast that Abbott Laboratories will post 2.86 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. The ex-dividend date is Thursday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.94%. Abbott Laboratories’s payout ratio is 430.79%.

In related news, EVP Stephen R. Fussell sold 13,313 shares of the company’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total transaction of $836,588.92. Following the transaction, the executive vice president now directly owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian J. Blaser sold 23,866 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $55.55, for a total value of $1,325,756.30. Following the transaction, the insider now directly owns 146,387 shares in the company, valued at $8,131,797.85. The disclosure for this sale can be found here. Insiders have sold 374,458 shares of company stock worth $20,752,706 over the last ninety days. 0.76% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. Rowland & Co. Investment Counsel ADV acquired a new position in Abbott Laboratories during the fourth quarter valued at $102,000. Icon Wealth Partners LLC acquired a new position in Abbott Laboratories during the fourth quarter valued at $102,000. Heritage Trust Co raised its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the period. Tributary Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at $106,000. Finally, Thompson Davis & CO. Inc. raised its position in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the period. 70.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/02/14/abbott-laboratories-abt-given-consensus-recommendation-of-buy-by-analysts.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.